{"DataElement":{"publicId":"7028278","version":"1","preferredName":"Endometrial Carcinoma Additional Pathologic Findings Type","preferredDefinition":"The response indicating any additional pathological findings identified.","longName":"EDMTR_ADD_PTH_TYP","context":"OCG","contextVersion":"1","DataElementConcept":{"publicId":"7027440","version":"1","preferredName":"Endometrial Carcinoma Additional Pathologic Finding","preferredDefinition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation._Added; extra; further._Caused by or altered by or manifesting disease or pathology._Clinical, laboratory or molecular evidence, or absence of evidence of disease.","longName":"3104218v1.0:6270533v1.0","context":"OCG","contextVersion":"1","ObjectClass":{"publicId":"3104218","version":"1","preferredName":"Endometrial Carcinoma","preferredDefinition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation. -- 2004","longName":"C7558","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Endometrial Carcinoma","conceptCode":"C7558","definition":"A malignant tumor arising from the epithelium that lines the cavity of the uterine body.  The vast majority of endometrial carcinomas are adenocarcinomas; squamous cell and adenosquamous carcinomas represent a minority of the cases.  Endometrioid adenocarcinoma is the most frequently seen variant of endometrial adenocarcinoma.  Uterine bleeding is an initial clinical sign.  The prognosis depends on the stage of the tumor, the depth of myometrial wall invasion, and the degree of differentiation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F3C580-07AC-1DC3-E040-BB89AD434E7E","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"ONEDATA","dateModified":"2010-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6270533","version":"1","preferredName":"Additional Pathologic Finding","preferredDefinition":"Added; extra; further.:Caused by or altered by or manifesting disease or pathology.:Clinical, laboratory or molecular evidence, or absence of evidence of disease.","longName":"C25406:C25610:C3367","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Additional","conceptCode":"C25406","definition":"Added; extra; further.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Finding","conceptCode":"C3367","definition":"Clinical, laboratory or molecular evidence, or absence of evidence of disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BA443E2-9E52-6737-E053-F662850A1EAE","latestVersionIndicator":"Yes","beginDate":"2018-05-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-05-07","modifiedBy":"ONEDATA","dateModified":"2018-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95AEAC19-2868-2284-E053-F662850AA15A","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"HARTLEYG","dateModified":"2019-10-30","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7027557","version":"1","preferredName":"Endometrial Carcinoma Pathologic Findings Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"7027557v1.0","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other (specify)","valueDescription":"Other","ValueMeaning":{"publicId":"5697874","version":"1","preferredName":"Other","longName":"5697874","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A253837-4DE2-5542-E053-F662850A338C","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-03-07","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95B1D78A-47F0-4361-E053-F662850AF49E","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"},{"value":"None idenified","valueDescription":"None","ValueMeaning":{"publicId":"4001711","version":"1","preferredName":"None","longName":"4001711","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED6DCE6B-B411-EF30-E040-BB89AD4369A8","latestVersionIndicator":"Yes","beginDate":"2013-12-13","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2013-12-13","modifiedBy":"GDEEN","dateModified":"2024-01-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"95B1D78A-482C-4361-E053-F662850AF49E","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","deletedIndicator":"No"},{"value":"Atypical hyperplasia/Endometrial intraepithelial neoplasia (EIN)","valueDescription":"Atypical Endometrial Hyperplasia And/Or Endometrial Intraepithelial Neoplasia","ValueMeaning":{"publicId":"7027559","version":"1","preferredName":"Atypical Endometrial Hyperplasia And/Or Endometrial Intraepithelial Neoplasia","longName":"7027559","preferredDefinition":"An endometrial hyperplasia characterized by cytologic and architectural changes which may lead to endometrial carcinoma.  Despite the atypical features and possible course, there is debate on whether to consider this a neoplasm.  The relationship with endometrial intraepithelial neoplasia is also unclear.: Used to indicate that either or both of two items or options may be valid.: A premalignant neoplastic process that affects the endometrial epithelium and glands. It is characterized by architectural glandular alterations and cytological abnormalities in the epithelial cells. The lesion exceeds 1 mm in maximum linear dimension.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atypical Endometrial Hyperplasia","conceptCode":"C4654","definition":"An endometrial hyperplasia characterized by cytologic and architectural changes which may lead to endometrial carcinoma.  Despite the atypical features and possible course, there is debate on whether to consider this a neoplasm.  The relationship with endometrial intraepithelial neoplasia is also unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia","conceptCode":"C27789","definition":"A neoplastic clonal expansion of endometrial glands characterized by cytologic changes of the epithelium and the presence of an increased number of endometrial glands. The glands form crowded aggregates with tubular or branching patterns which are cytologically distinct from the background architectural and cytological pattern. It is associated with molecular changes seen in endometrioid endometrial carcinoma, including microsatellite instability, PAX2 inactivation, and PTEN, KRAS, and CTNNB1 gene mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"95B1D78A-47FF-4361-E053-F662850AF49E","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"ONEDATA","dateModified":"2019-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"969C1BB0-8D0E-5682-E053-F662850ACBDB","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-11-05","modifiedBy":"ONEDATA","dateModified":"2019-11-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95B1D78A-47CF-4361-E053-F662850AF49E","latestVersionIndicator":"Yes","beginDate":"2019-10-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-24","modifiedBy":"HARTLEYG","dateModified":"2019-11-05","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5806857","version":"1","longName":"HCMI (Human Cancer Models Initiative)","context":"OCG","ClassificationSchemeItems":[{"publicId":"7026248","version":"1","longName":"Endometrial","context":"OCG"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Additional pathologic findings","type":"Preferred Question Text","description":"Additional pathologic findings","url":null,"context":"OCG"}],"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"95C4EA3B-A791-60D8-E053-F662850AB208","latestVersionIndicator":"Yes","beginDate":"2019-10-25","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-10-25","modifiedBy":"HARTLEYG","dateModified":"2019-11-07","changeDescription":"Curated to support Endometrial content_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}